Join
Live feed
·
PRReleasevia Quantisnow
Cassava Sciences Inc. logo

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

ByQuantisnow·Wall Street's wire, on your screen.
SAVA· Cassava Sciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SAVA (Cassava Sciences Inc.) and more on Quantisnow.